We publish no single base value for GE HealthCare. Our valuation methods put it between $70.26 and $91.91 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate.
| Method | Value | vs price | Basis |
|---|---|---|---|
| Discounted cash flow | $91.91 | +12.3% | free cash flow $1.89bn, growth 6.88% for 5 years, then fading to 3% over 5 more, discounted at 8.91%; stress floor $55.72 |
| Exit multiple (P/E) | $70.26 | -14.1% | earnings per share $5.02 valued at 16.68× (the stock's own median P/E) in 5 years, discounted back |
| Sum of the parts | — | — | no sum of the parts: this run holds no segment disclosure for the name |
| Price to sales | — | — | not reached: the cash-flow or earnings methods produced an anchor, so this fallback was not run |
| Tangible book | — | — | used only for lenders, where book value is the business |
| Price to FFO (REITs) | — | — | used only for REITs |
Each working is rebuilt by code from the valuation's own figures and checked against the published value.
The discount rate:
| Risk-free rate | 5.13% (10-year US Treasury yield) |
| Company's own beta | 0.76 (5 years of monthly returns against the S&P 500; standard error 0.35) |
| Peer beta | 0.78 (median of 15 S&P 500 Health Care Equipment companies) |
| Blend of own and peers | 0.77 (55% own, 45% peers, weighted by how precisely the company's own beta is measured) |
| Adjusted beta | 0.84 (0.67 × 0.77 + 0.33, pulled toward the market's 1.0) |
| Equity risk premium | 4.5% |
| Discount rate = risk-free + adjusted beta × premium | 8.91% |
Free cash flow grows 6.88% a year for 5 years, then fades in equal steps toward 3% over 5 more; each year is discounted by 1 ÷ (1 + rate)^year:
| Year | Growth | Free cash flow | Discount factor | Present value |
|---|---|---|---|---|
| Now | — | $1.89bn | — | — |
| Year 1 | 6.88% | $2.02bn | 0.9182 | $1.85bn |
| Year 2 | 6.88% | $2.16bn | 0.8431 | $1.82bn |
| Year 3 | 6.88% | $2.31bn | 0.7741 | $1.79bn |
| Year 4 | 6.88% | $2.47bn | 0.7108 | $1.75bn |
| Year 5 | 6.88% | $2.64bn | 0.6526 | $1.72bn |
| Year 6 | 6.23% | $2.80bn | 0.5992 | $1.68bn |
| Year 7 | 5.59% | $2.96bn | 0.5502 | $1.63bn |
| Year 8 | 4.94% | $3.10bn | 0.5052 | $1.57bn |
| Year 9 | 4.29% | $3.24bn | 0.4639 | $1.50bn |
| Year 10 | 3.65% | $3.35bn | 0.4259 | $1.43bn |
| Terminal value = year-10 cash flow × (1 + 3%) ÷ (8.91% − 3%) | $58.45bn |
| Terminal value in today's money | $24.90bn |
| Present value of years 1–10 | $16.74bn |
| Total present value | $41.63bn |
| Shares outstanding | 453.00m |
| Value per share = total ÷ shares | $91.91 |
How the DCF value moves with the discount rate and the starting growth (the middle cell is the published value):
| Discount rate | Growth 1.88% | Growth 6.88% | Growth 11.88% |
|---|---|---|---|
| 7.91% | $81.60 | — | $151.12 |
| 8.91% | $67.93 | $91.91 | $123.83 |
| 9.91% | $58.21 | $78.12 | — |
The same DCF at each beta, starting growth unchanged:
| Beta | Value | Discount rate | DCF value |
|---|---|---|---|
| Company's own beta | 0.76 | 8.55% | — |
| Peer beta | 0.78 | 8.64% | — |
| Adjusted beta (used) | 0.84 | 8.91% | $91.91 |
Earnings per share grow on the same fading path as the DCF:
| Year | Growth | Earnings per share |
|---|---|---|
| Now | — | $5.02 |
| Year 1 | 6.88% | $5.37 |
| Year 2 | 5.72% | $5.67 |
| Year 3 | 4.90% | $5.95 |
| Year 4 | 4.33% | $6.21 |
| Year 5 | 3.93% | $6.45 |
| Earnings per share in year 5 | $6.45 |
| Exit P/E (the stock's own median P/E) | 16.68× |
| Value in 5 years = earnings × P/E | $107.65 |
| Discounted at 8.91% over 5 years: ÷ 1.5323 | $70.26 |
We publish no single base value for GE HealthCare. Our valuation methods put it between $70.26 and $91.91 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate.
One-year price simulation: a 10% chance the price is below $58.44 and a 10% chance it is above $124.93 in a year; a 56% chance it is higher than today's $81.84, from 29.49% volatility. The simulation assumes the price drifts up at our discount rate of 8.91% a year.
At $81.84 the price implies free cash flow growing 5.0% a year for five years and then fading toward 3% over five more; its revenue has grown 6.9%.
| Week | Price | Base value |
|---|---|---|
| 2 Oct 2026 | $64.29 | — |
| 9 Oct 2026 | $65.74 | — |
| 16 Oct 2026 | $69.57 | — |
| 23 Oct 2026 | $71.45 | — |
| 30 Oct 2026 | $76.57 | — |
| 6 Nov 2026 | $82.38 | — |
| 12 Nov 2026 | $81.84 | — |
Data as of 12 Nov 2026; financials to 30 Sep 2026. Sources: company filings via EODHD, SEC EDGAR, US Treasury. How these values are computed. Not investment advice.
Run a full Desk Run on GEHC · GE HealthCare company page · Call and put prices